Researches in type 2 diabetes and non-alcoholic fatty liver disease have been made in recent years.The intimate connection between these two diseases has been analysed and explored.Whether non-alcoholic fatty liver disease is a hepatic complication of type 2 diabetes remains to be elucidated.The poor outcome of liver disease in patients with type 2 diabetes should be emphasized.

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disorder, affecting 10%-24% of the general population, and the incidence is much higher (70% -80% ) in type 2 diabetic patients. Recent studies indicate that fatty liver is an emerging problem in the Asia-Pacific region and China. The community prevalence of NAFLD in Shanghai is 15%. A large body of evidences suggests that NAFLD is the hepatic manifestation of the metabolic syndrome. NAFLD is not only associated with the metabolic syndrome, it also predicts the development of type 2 diabetes and cardiovascular disease (CVD). The liver is a central organ for controlling and regulating glucose and lipids metabolism; intrahepatocellular lipid accumulation plays a key role in the development of metabolic-ally related disorders. It is crucial that specialists, especially endocrinologists, and practising clinicians should be aware of the strong association between NAFLD and increased risks of diabetes and CVD, NAFLD should be diagnosed correctly and defined timely in regarding its role as risk factors of underlying diabetes and CVD.

The progress in nonalcoholic fatty liver disease(NAFLD) research has shown an important role of hepatic steatosis in triggering insulin resistance and glucose/lipid metabolic disorders.As an early reversible therapeutic target for metabolic diseases,NAFLD has attracted increasing attention from endocrinologists and gastroenterologists,as well as deeping the studies in this field.Based on the recent progress in NAFLD research,this review mainly presents the new understanding and concept of NAFLD,discusses the features of the new guidelines and concensus for NAFLD treatment,and introduces some updated developments in NAFLD diagnosis and therapy.Furthermore,future directions of NAFLD research are also predicted in the article.

Diabetes Mellitus, Type 2 ; complications ; Humans ; Non-alcoholic Fatty Liver Disease ; complications

Objective To explore the before taking finasteride on transurethral plasmakinetic resection of prostate(TUPKVP)patients about IPSS,QOL,Qmax,PVR and other indicators.Methods 180 cases with benign prostatic hyperplasia were randomly divided into observation group and control group,90 cases in each group.Observation group and control group were given conventional therapy and the observed patients took 5 mg of finasteride everyday one week before surgery,all patients were followed up for 1 month.The two groups of TUPKVP patients were compared about IPSS,QOL,Qmax and PVR,intraoperative blood loss,operation time,irrigation fluid volume indicators.Results 180 patients were given successfully TUPKVP surgery.IPSS,QOL,Qmax and PVR contrast were significantly improved after treatment(t=5.11,7.01,3.06,6.17,11.82,4.13,4.52,5.17,all P＜0.05).IPSS,Qmax,PVR of the observation group after treatment was significantly better than that of the control group(t=11.35,5.26,3.12,all P＜0.05),the QOL difference between the two groups after treatment was not statistically significant(P＞0.05).The cure rate of the observation group was 87.8％,which was significantly higher than 63.33％ in the control group(x2=14.56,P＜0.05).Intraoperative flushing fluid volume,intraoperative blood loss,duration of surgery in the observation group were significantly different compared with the control group,(t=21.15、43.12,5.33,all P＜0.05).Conclusion The preoperative taking finasteride can reduce TUPKVP blood loss and flushing fluid volume,shorten operation time and effectively improve the security of the operation.

Nonalcoholic fatty liver disease (NAFLD) is associated with obesity, type 2 diabetes,dyslipidemia, hypertension, and metabolic syndrome.It likely represents hepatic manifestation of metabolic syndrome. The prevalence of NAFLD has been estimated to be 20％-30％ in the general population. However, it is much higher in type 2 diabetic patients. Several epidemiological studies indicate that NAFLD is linked to an increased risk of cardiovascular disease( CVD), which is independent of underlying cardiometabolic risk factors. This suggests that NAFLD may also be actively involved in the pathogenesis. The possible molecular mediators linking NAFLD and atherosclerosis(AS) include the release of pro-atherogenic factors by oxidative stress and inflammation as well as atherogenic dyslipidemia, abnormal adipose factors, and insulin resistance, finally aggravating progression of CVD. In this article, the relationship and possible mechanisms between NAFLD and AS are reviewed.

Microsomal triglyceride transfer protein (MTP) is a key transfer protein in lipid metabolism and is mainly expressed in the hepatocytes and enterocytes.It plays an important role in transferring triglyceride as well as in assembly and secretion of very low density lipoprotein.Recent studies have shown that MTP is closely related to the onset and development of non-alcoholic fatty liver disease.

Nonalcoholic fatty liver disease(NAFLD)has become one of the most common liver diseases in the world.Considering the important role of insulin resistance in its pathogenic mechanisms,insulin sensitizers are becoming the promising pharmacological strategies for NAFLD.We collected and analyzed the relevant articles in recent years and found that pioglitazone,rosiglitazone and metformin could improve liver enzymes and insulin sensitivity of NAFLD.However,only pioglitazine was supported in ameliorating liver histology by envidences from randomized,double-blinded,controlled clinical trials.There were no much obvious adverse effects in NAFLD patients who received insulin senitizers.Small or medium samples and no more than 2 years of treatment course may be the major limitation of current studies.Future information derived from well-designed running trials will be useful in defining the clinical implications of insulin sensitizers in the treatment of NAFLD.

Objective Tanycytes(TAs) is a specialized eppendymal glia that locates mostly in the ventral lateral wall of the ventricle III and median eminence(ME).Due to its peculiar location and directly exposure to the cerebrospinal fluid,blood,neuroendocrine hormones and neurons,tanycytes play an important role in the brain barrier system,brain-CSF neurohumoral circuit and immune-neuroendocrine network.They maintain immature characters during the adulthood and have naturally conducted the neuroregeneration process in the adult hypothalamus of mammal animals.This research was designed to identify tanycytes(TAs) in postnatal 7 days of Wistar rats and then establish the cell model of TAs for further study.Methods Tanycytes of postnatal 7 days of Wistar rats were identified by the immunohistochemical technology using glial fibrillary acidic protein(GFAP) and vimentin(VIM),which are the intermediate filament markers of glia cells.The qualitative analysis was performed by the NADPH-d stain of nitric oxide sythenase(NOS).Primary TAs model was established by the cell culture technique and identified by the same methods as in vivo.Results Primary cultured TAs expressed VIM,GFAP and NOS which was identical with those in vivo.Conclusion Cell model of TAs from postnatal 7days of Wistar rats in vitro has been established and TAs could be used as a proper substrate for transplanting.

Objective To investigate the effects of IL-15 eukaryotic expression plasmid on the Ag-specific immune responses induced by HPV 16 E7 vaccine in mice.Methods An eukaryotic expression plasmid encoding IL-15 gene coding region was constructed and named as pcDNA3.1IL-15.Female BALB/c mice were injected intramuscularly with pcDNA3.1-IL-15 and HPV16 E7 gene vaccine.After the immunization,the concentration of serum IFN-? were tested.Single-cell suspensions of splenocytes were prepared from mice and were re-stimulated with HPV16 E7 protein.Then,the T cell proliferation assay was measured by the MTT method.Results The concentration of serum IFN-? in mice after co-injection with pcDNA3.1-IL-15 and pcDNA3.1-E7 was raised to 414.1pg/ml,which was significantly higher than that of mice co-injected with pcDNA3.1 and pcDNA3.1-E7 or mice injected with pcDNA3.1-E7 only(P